MX362550B - Inhibidores ciclicos de glutaminasa. - Google Patents
Inhibidores ciclicos de glutaminasa.Info
- Publication number
- MX362550B MX362550B MX2014005928A MX2014005928A MX362550B MX 362550 B MX362550 B MX 362550B MX 2014005928 A MX2014005928 A MX 2014005928A MX 2014005928 A MX2014005928 A MX 2014005928A MX 362550 B MX362550 B MX 362550B
- Authority
- MX
- Mexico
- Prior art keywords
- glutaminase
- heterocyclic inhibitors
- heterocyclic compounds
- heterocyclic
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente invención se refiere compuestos heterocíclicos de fórmula (I) como se define además en la presente, y preparaciones farmacéuticas de los mismos. La invención además se refiere a métodos para tratar cáncer, enfermedades inmunológicas o neurológicas usando los compuestos heterocíclicos de la invención.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161562266P | 2011-11-21 | 2011-11-21 | |
US201261665370P | 2012-06-28 | 2012-06-28 | |
US201261727195P | 2012-11-16 | 2012-11-16 | |
PCT/US2012/065816 WO2013078123A1 (en) | 2011-11-21 | 2012-11-19 | Heterocyclic inhibitors of glutaminase |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014005928A MX2014005928A (es) | 2014-08-27 |
MX362550B true MX362550B (es) | 2019-01-24 |
Family
ID=48470227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005928A MX362550B (es) | 2011-11-21 | 2012-11-19 | Inhibidores ciclicos de glutaminasa. |
Country Status (26)
Country | Link |
---|---|
EP (2) | EP2782570B1 (es) |
JP (3) | JP6031527B2 (es) |
KR (2) | KR102042290B1 (es) |
CN (2) | CN104220070B (es) |
AR (1) | AR090398A1 (es) |
AU (1) | AU2012340866B2 (es) |
BR (1) | BR112014012129A8 (es) |
CA (1) | CA2856386C (es) |
CY (1) | CY1122707T1 (es) |
DK (1) | DK2782570T3 (es) |
EA (2) | EA201692166A1 (es) |
ES (1) | ES2761866T3 (es) |
HK (1) | HK1204768A1 (es) |
HR (1) | HRP20192144T1 (es) |
HU (1) | HUE047642T2 (es) |
IL (2) | IL232665A0 (es) |
LT (1) | LT2782570T (es) |
MX (1) | MX362550B (es) |
PL (1) | PL2782570T3 (es) |
PT (1) | PT2782570T (es) |
RS (1) | RS59705B1 (es) |
SG (2) | SG11201402305WA (es) |
SI (1) | SI2782570T1 (es) |
TW (1) | TWI585084B (es) |
WO (1) | WO2013078123A1 (es) |
ZA (2) | ZA201404518B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
EP2895623B1 (en) | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
SG11201503720SA (en) * | 2012-11-16 | 2015-06-29 | Calithera Biosciences Inc | Heterocyclic glutaminase inhibitors |
BR112015011756A2 (pt) | 2012-11-21 | 2017-07-11 | Agios Pharmaceuticals Inc | inibidores da glutamase e métodos de uso |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014089048A1 (en) * | 2012-12-03 | 2014-06-12 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
US9457016B2 (en) | 2013-08-29 | 2016-10-04 | New York University | Methods for treating polycystic kidney disease |
WO2015061432A1 (en) * | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
CN112920180A (zh) * | 2014-01-06 | 2021-06-08 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
CN103880777B (zh) * | 2014-03-06 | 2015-12-30 | 陕西科技大学 | 一种制备双噻二唑二胺的方法 |
WO2015138902A1 (en) * | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
KR20160127149A (ko) * | 2014-03-21 | 2016-11-02 | 아지오스 파마슈티컬스 아이엔씨. | 화합물 및 이의 사용 방법 |
PL3137460T3 (pl) * | 2014-04-30 | 2020-04-30 | Pfizer Inc. | Pochodne diheterocyklu połączonego cykloalkilem |
GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US9687485B2 (en) * | 2014-06-13 | 2017-06-27 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
SI3164394T1 (sl) | 2014-07-03 | 2020-08-31 | Board Of Regents, The University Of Texas System | GLS1 inhibitorji za zdravljenje bolezni |
WO2016007647A1 (en) | 2014-07-09 | 2016-01-14 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
CA2957225A1 (en) * | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
WO2016160980A1 (en) * | 2015-03-30 | 2016-10-06 | Calithera Biosciences, Inc. | Methods of administering glutaminase inhibitors |
JP6944377B2 (ja) * | 2015-04-06 | 2021-10-06 | キャリセラ バイオサイエンシーズ, インコーポレイテッド | グルタミナーゼの阻害剤を用いる肺がんの処置 |
CN107921044B (zh) | 2015-06-30 | 2022-01-21 | 德州大学***董事会 | 用于治疗疾病的gls1抑制剂 |
SG11201802830QA (en) | 2015-10-05 | 2018-05-30 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
US10323028B2 (en) | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
SG11201804664XA (en) | 2015-12-22 | 2018-07-30 | Univ Texas | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
US10195197B2 (en) | 2016-08-25 | 2019-02-05 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
US10278968B2 (en) * | 2016-08-25 | 2019-05-07 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
EP3576726A1 (en) | 2017-02-06 | 2019-12-11 | Massachusetts Institute Of Technology | Methods and products related to glutaminase inhibitors |
CN107137401A (zh) * | 2017-03-28 | 2017-09-08 | 刘纪君 | 一种治疗产后抑郁症的药物组合物 |
CN106860460B (zh) * | 2017-03-29 | 2019-04-23 | 上海市第一人民医院 | 谷氨酰胺酶抑制剂cb-839在制备治疗***敏感型子宫内膜癌的药物中的应用 |
CN110741003B (zh) | 2017-06-13 | 2021-07-23 | 南京明德新药研发有限公司 | 作为gls1抑制剂的化合物 |
EP3697764A4 (en) | 2017-10-18 | 2021-07-21 | Board Of Regents, The University Of Texas System | GLUTAMINASE INHIBITOR THERAPY |
PT3868758T (pt) * | 2018-10-16 | 2023-02-16 | Medshine Discovery Inc | Derivados de tiadiazole e sua utilização como inibidores gls1 de para o tratamento de cancro |
CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
KR102649592B1 (ko) * | 2021-08-18 | 2024-03-20 | 한국화학연구원 | 신규한 마크로사이클 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
CN1229110C (zh) | 1997-07-29 | 2005-11-30 | 阿尔康实验室公司 | 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物 |
WO1999009825A1 (en) | 1997-08-29 | 1999-03-04 | Elan Pharmaceuticals, Inc. | Method of preventing neuronal death |
EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
DK1654002T4 (da) | 2003-08-07 | 2014-02-17 | Allergan Inc | Sammensætninger til fremføring af terapeutiske midler til øjnene |
US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
AU2008282728B2 (en) * | 2007-08-02 | 2012-04-19 | Amgen Inc. | Pl3 kinase modulators and methods of use |
MX2010010339A (es) | 2008-03-27 | 2010-10-07 | Gruenenthal Gmbh | Ciclohexildiaminas sustituidas. |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) * | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
-
2012
- 2012-11-19 LT LTEP12850989.0T patent/LT2782570T/lt unknown
- 2012-11-19 BR BR112014012129A patent/BR112014012129A8/pt not_active Application Discontinuation
- 2012-11-19 KR KR1020147016922A patent/KR102042290B1/ko active IP Right Grant
- 2012-11-19 WO PCT/US2012/065816 patent/WO2013078123A1/en active Application Filing
- 2012-11-19 DK DK12850989T patent/DK2782570T3/da active
- 2012-11-19 JP JP2014542546A patent/JP6031527B2/ja not_active Expired - Fee Related
- 2012-11-19 RS RS20191617A patent/RS59705B1/sr unknown
- 2012-11-19 PL PL12850989T patent/PL2782570T3/pl unknown
- 2012-11-19 EA EA201692166A patent/EA201692166A1/ru unknown
- 2012-11-19 EP EP12850989.0A patent/EP2782570B1/en active Active
- 2012-11-19 SI SI201231702T patent/SI2782570T1/sl unknown
- 2012-11-19 HU HUE12850989A patent/HUE047642T2/hu unknown
- 2012-11-19 PT PT128509890T patent/PT2782570T/pt unknown
- 2012-11-19 CN CN201280067512.9A patent/CN104220070B/zh not_active Expired - Fee Related
- 2012-11-19 SG SG11201402305WA patent/SG11201402305WA/en unknown
- 2012-11-19 ES ES12850989T patent/ES2761866T3/es active Active
- 2012-11-19 AU AU2012340866A patent/AU2012340866B2/en not_active Ceased
- 2012-11-19 CA CA2856386A patent/CA2856386C/en active Active
- 2012-11-19 MX MX2014005928A patent/MX362550B/es active IP Right Grant
- 2012-11-19 EP EP19189654.7A patent/EP3620162A1/en not_active Withdrawn
- 2012-11-19 KR KR1020197032287A patent/KR20190127971A/ko not_active Application Discontinuation
- 2012-11-19 SG SG10201607685SA patent/SG10201607685SA/en unknown
- 2012-11-19 CN CN201810569234.6A patent/CN108785305B/zh not_active Expired - Fee Related
- 2012-11-19 EA EA201491012A patent/EA026656B1/ru not_active IP Right Cessation
- 2012-11-21 AR ARP120104366A patent/AR090398A1/es active IP Right Grant
- 2012-11-21 TW TW101143424A patent/TWI585084B/zh not_active IP Right Cessation
-
2014
- 2014-05-18 IL IL232665A patent/IL232665A0/en unknown
- 2014-06-19 ZA ZA2014/04518A patent/ZA201404518B/en unknown
-
2015
- 2015-06-04 HK HK15105312.3A patent/HK1204768A1/xx unknown
-
2016
- 2016-03-10 ZA ZA2016/01655A patent/ZA201601655B/en unknown
- 2016-09-13 JP JP2016178240A patent/JP6329226B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-19 JP JP2018080830A patent/JP6577623B2/ja not_active Expired - Fee Related
- 2018-06-12 IL IL259958A patent/IL259958B/en active IP Right Grant
-
2019
- 2019-11-28 HR HRP20192144TT patent/HRP20192144T1/hr unknown
- 2019-12-16 CY CY20191101318T patent/CY1122707T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
PH12017502141A1 (en) | Compounds and their methods of use | |
EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
IN2015DN00827A (es) | ||
NZ700928A (en) | Dna-pk inhibitors | |
IN2014MN00988A (es) | ||
EA201291143A1 (ru) | Пиразолилхиназолиновые ингибиторы киназы | |
MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
EA201591745A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh | |
TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
EA201391106A1 (ru) | Новые гетероциклические производные | |
MX2014002836A (es) | Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa. | |
IN2015DN01151A (es) | ||
EA201690386A1 (ru) | Соединения и композиции в качестве ингибиторов mek | |
PH12015501038A1 (en) | Inhibitors of iap | |
MX2014007364A (es) | Nuevas carboxamidas heterociclicas como modulares de la activadad de cinasas. | |
NZ748422A (en) | Heterocyclic glutaminase inhibitors | |
UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak | |
UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази | |
UA109932C2 (xx) | Циклопропіламіни як інгібітори lsd1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |